Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:10 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
NCT05618366 · Weill Medical College of Cornell University · PHASE1 · terminated · last registry update 2026-04-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low accrual” | – | Registry record, Weill Medical College of Cornell University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against BCL2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-09Phase 3 first posted: Beijing InnoCare Pharma Tech Co., Ltd., Mesutoclax (ICP-248) + Azacitidine (AZA) (NCT07925190)
- 2026-10-21Results posted on the registry: AbbVie, Venetoclax + Ibrutinib (NCT05105841)
- 2026-10-20Also stopped (suspended): City of Hope Medical Center, 8-Chloroadenosine + Venetoclax (NCT05263284)
- 2026-10-20Also stopped (suspended): City of Hope Medical Center, Azacitidine + Regorafenib (NCT06454409)
- 2026-10-20Also stopped (suspended): City of Hope Medical Center, Decitabine + Pembrolizumab (NCT03969446)
- 2026-10-19Results posted on the registry: Sanofi, SAR443579 + venetoclax (NCT06508489)
- 2026-10-19Also stopped (terminated): Sanofi, SAR443579 + venetoclax (NCT06508489)
- 2026-10-16Also stopped (terminated): M.D. Anderson Cancer Center, Azacitidine + Venetoclax (NCT04062266)
- 2026-10-07Results posted on the registry: Nicole Lamanna, Bendamustine + Venetoclax (NCT03609593)
- 2026-10-06Results posted on the registry: National Cancer Institute (NCI), Cytarabine + Daunorubicin (NCT04817241)
- 2026-10-01Also stopped (terminated): Bristol-Myers Squibb, BMS-986497 + Azacitidine (NCT06419634)
- 2026-10-01Also stopped (suspended): Institut Paoli-Calmettes, Dasatinib (NCT06055621)
- 2026-08-25Also stopped (suspended): National Cancer Institute (NCI), Azacitidine + Iadademstat (NCT06514261)
- 2026-08-24Also stopped (suspended): National Cancer Institute (NCI), Decitabine and Cedazuridine + Venetoclax (NCT06802523)
- 2026-08-24Also stopped (terminated): University of Michigan Rogel Cancer Center, Venetoclax + FLAG or CLAG Protocol (NCT05780879)
- 2026-08-20Also stopped (terminated): M.D. Anderson Cancer Center, Akt/ERK Inhibitor ONC201 + Venetoclax (NCT02392572)
- 2026-08-05Also stopped (withdrawn): Memorial Sloan Kettering Cancer Center, Azacitidine (AZA) + Venetoclax (NCT06903702)
- 2026-07-29Phase 3 first posted: Ruijin Hospital, Mitoxantrone Hydrochloride Liposome + Cytarabine (NCT07735117)
- 2026-07-20Phase 3 first posted: The Second Affiliated Hospital of Kunming Medical University, a drug against BCL2 (NCT07712848)
- 2026-07-13Also stopped (terminated): Antonio M Jimenez Jimenez, Venetoclax + Azacitidine (NCT06158100)
- 2026-07-10Results posted on the registry: Dana-Farber Cancer Institute, Venetoclax (NCT03054896)
- 2026-06-11Results posted on the registry: University of Colorado, Denver, Azacitidine + Venetoclax (NCT03573024)
- 2026-06-10Also stopped (terminated): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Venetoclax Oral Tablet [Venclexta] (NCT05025423)
- 2026-06-09Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Venetoclax Oral Tablet [Venclexta] (NCT05025423)
- 2026-06-05Also stopped (terminated): M.D. Anderson Cancer Center, Azacitidine + Venetoclax (NCT04550442)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision